Houston medical institutions launch $6M kidney research incubator

NIH funding

Houston institutions have landed $6.25 million in NIH funding to launch the HAI-KUH research training program. Photo via UH.

Institutions within Houston’s Texas Medical Center have launched the Houston Area Incubator for Kidney, Urologic and Hematologic Research Training (HAI-KUH) program. The incubator will be backed by $6.25 million over five years from the National Institutes of Health and aims to create a training pipeline for researchers.

HAI-KUH will include 58 investigators from Baylor College of Medicine, Texas Children’s Hospital, the University of Texas Health Science Center at Houston, University of Houston, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University and Texas A&M University Institute of Biosciences and Technology. The program will fund six predoctoral students and six postdoctoral associates. Trainees will receive support in scientific research, professional development and networking.

According to the organizations, Houston has a high burden of kidney diseases, hypertension, sickle cell disease and other nonmalignant hematologic conditions. HAI-KUH will work to improve the health of patients by building a strong scientific workforce that leverages the team's biomedical research resources to develop research skills of students and trainees and prepare them for sustained and impactful careers. The funding comes through the National Institute of Diabetes and Digestive and Kidney Diseases.

The principal investigators of the project include Dr. Alison Bertuch, professor of pediatric oncology and molecular and human genetics at BCM; Peter Doris, professor and director of the Institute of Molecular Medicine Center for Human Genetics at UT Health; and Margaret Goodell, professor and chair of the Department of Molecular and Cellular Biology at Baylor.

“This new award provides unique collaborative training experiences that extend beyond the outstanding kidney, urology, and hematology research going on in the Texas Medical Center,” Doris said in a news release. “In conceiving this award, the National Institute of Diabetes and Digestive and Kidney Diseases envisioned trainee development across the full spectrum of skills required for professional success.”

Jeffrey Rimer, a professor of Chemical Engineering, is a core investigator on the project and program director at UH. Rimer is known for his breakthroughs in using innovative methods in control crystals to help treat malaria and kidney stones. Other co-investigators include Dr. Wolfgang Winkelmeyer (Baylor), Oleh Pochynyuk (UTHealth), Dr. Rose Khavari (Houston Methodist) and Pamela Wenzel (UT Health).

“This new NIH-sponsored training program will enable us to recruit talented students and postdocs to work on these challenging areas of research,” Rimer added in a release.

From Your Site Articles
A new AI tool from a Baylor College of Medicine Lab could help better diagnose specific types of autism spectrum disorder, epilepsy and developmental delay disorders. Photo via Getty Images.

Houston lab develops AI tool to improve neurodevelopmental diagnoses

developing news

One of the hardest parts of any medical condition is waiting for answers. Speeding up an accurate diagnosis can be a doctor’s greatest mercy to a family. A team at Baylor College of Medicine has created technology that may do exactly that.

Led by Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology at Baylor and principal investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, the scientists have developed an artificial intelligence-based approach that will help doctors to identify genes tied to neurodevelopmental disorders. Their research was recently published the American Journal of Human Genetics.

According to its website, Dhindsa Lab uses “human genomics, human stem cell models, and computational biology to advance precision medicine.” The diagnoses that stem from the new computational tool could include specific types of autism spectrum disorder, epilepsy and developmental delay, disorders that often don’t come with a genetic diagnosis.

“Although researchers have made major strides identifying different genes associated with neurodevelopmental disorders, many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered,” Dhindsa said in a news release.

Typically, scientists must sequence the genes of many people with a diagnosis, as well as people not affected by the disorder, to find new genes associated with a particular disease or disorder. That takes time, money, and a little bit of luck. AI minimizes the need for all three, explains Dhindsa: “We used AI to find patterns among genes already linked to neurodevelopmental diseases and predict additional genes that might also be involved in these disorders.”

The models, made using patterns expressed at the single-cell level, are augmented with north of 300 additional biological features, including data on how intolerant genes are to mutations, whether they interact with other known disease-associated genes, and their functional roles in different biological pathways.

Dhindsa says that these models have exceptionally high predictive value.

“Top-ranked genes were up to two-fold or six-fold, depending on the mode of inheritance, more enriched for high-confidence neurodevelopmental disorder risk genes compared to genic intolerance metrics alone,” he said in the release. “Additionally, some top-ranking genes were 45 to 500 times more likely to be supported by the literature than lower-ranking genes.”

That means that the models may actually validate genes that haven’t yet been proven to be involved in neurodevelopmental conditions. Gene discovery done with the help of AI could possibly become the new normal for families seeking answers beyond umbrella terms like “autism spectrum disorder.”

“We hope that our models will accelerate gene discovery and patient diagnoses, and future studies will assess this possibility,” Dhindsa added.

Research from Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital will help develop targeted treatments for individuals with auditory disorders. Photo via Getty Images.

Houston scientists make breakthrough in hearing science and treatment research

sounds good

Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital have successfully mapped which cell populations are responsible for processing different types of sounds.

Working with a team at the Oregon Health & Science University, the Houston scientists have classified where in the cochlear nucleus our brains connect with various sounds, including speech and music. The research was published in the new edition of Nature Communications.

“Understanding these cell types and how they function is essential in advancing treatments for auditory disorders,” Matthew McGinley, assistant professor of neuroscience at Baylor, said in a release. “Think of how muscle cells in the heart are responsible for contraction, while valve cells control blood flow. The auditory brainstem operates in a similar fashion — different cell types respond to distinct aspects of sound.”

Though scientists have long thought that there are distinct types of cells in the cochlear nucleus, they didn’t have tools to distinguish them until now.

Lead author on the study, Xiaolong Jiang, associate professor of neuroscience at Baylor, added: “This study not only confirms many of the cell types we anticipated, but it also unveils entirely new ones, challenging long-standing principles of hearing processing in the brain and offering fresh avenues for therapeutic exploration.”

Jiang and his team have cooked up a comprehensive cellular and molecular atlas of the cochlear nucleus, which will help them to create more targeted and more effective treatments for patients struggling with their hearing.

The strategies that aided them in creating these tools included single-nucleus RNA sequencing, which made it possible to define neuronal populations on a molecular level. Phenotypic categorizations of the cells were made possible with patch sequencing.

This is a watershed moment for the development of targeted treatments for individuals with auditory disorders, including those with impaired function in the auditory nerve, for whom cochlear implants don’t work.

“If we can understand what each cell type is responsible for, and with the identification of new subtypes of cells, doctors can potentially develop treatments that target specific cells with greater accuracy,” McGinley explains. “These findings, thanks to the work of our collaborative team, make a significant step forward in the field of auditory research and get us closer to a more personalized treatment for each patient.”

The University of Texas MD Anderson Cancer Center was recognized for advancements in electronic functionality, AI and robotics. Photo via mdanderson.org

Houston hospital named among smartest in the nation

hi, tech

Houston hospitals are chock-full of smart people. But they’re also equipped with lots of “smart” technology. In fact, five local hospitals appear on Newsweek’s new list of the world’s best “smart” hospitals.

To compile the list, Newsweek teamed up with data provider Statista to rank the world’s top 330 hospitals for the use of smart technology. The ranking factors were electronic functionality, telemedicine, digital imaging, artificial intelligence (AI), and robotics.

The highest-ranked Houston hospital is the University of Texas MD Anderson Cancer Center, appearing at No. 6. The hospital was recognized for advancements in electronic functionality, AI and robotics.

“MD Anderson has a significant opportunity and a responsibility to our many stakeholders to create a digital ecosystem that promotes collaboration and advances scientific discovery to enhance patient outcomes,” David Jaffray, the cancer center’s chief technology and digital officer, said in a 2021 news release.

“Through our ongoing focus on enabling the use of new technologies to place quantitative data in context for our researchers,” Jaffray added, “we foster cutting-edge oncology data science to inform our cancer discovery research and to accelerate translation of our research findings into benefits for cancer patients.”

Ahead of MD Anderson on the list are:

  1. Mayo Clinic in Rochester, Minnesota.
  2. Cleveland Clinic in Cleveland.
  3. Massachusetts General Hospital in Boston.
  4. Johns Hopkins Hospital in Baltimore.
  5. Mount Sinai Hospital in New York City.

Other Houston hospitals on the list are:

  • Houston Methodist Hospital, No. 11.
  • Baylor St. Luke’s Medical Center, No. 105.
  • Texas Children’s Hospital, No. 197.
  • Memorial Hermann-Texas Medical Center, No. 266.
CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

University of Houston-founded company secures $2.5M in NIH grant funding

all in the timing

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

Baylor College of Medicine's Jessica Watts, Dr. Jerome Pollet, and Dr. Paul Ling with Tess. Photo by Jackelin Reyna/Houston Zoo

Houston med school develops revolutionary mRNA vaccine for elephants

zoology biology

An innovative team from Baylor College of Medicine and Texas Children’s Hospital has worked with the Houston Zoo to develop a first-of-its-kind treatment for elephants, which has been administered to its first patient.

Tess, the beloved, 40-year-old matriarch of the Houston Zoo’s elephant herd, is recovering well after receiving the first-ever mRNA vaccine against elephant endotheliotropic herpesvirus (EEHV) 1A on Tuesday, June 18. The veterinary staff at the Houston Zoo will monitor Tess in the coming weeks to check her reaction and the efficacy of the vaccine.

EEHV 1A is a deadly infection for Asian Elephants. While generally benign in African Elephants, Asian Elephants can develop fatal hemorrhages. The fatality rate is a whopping 80 percent, making it one of the most serous threats to elephant populations outside of humans.

Anti-viral drugs have some effect on the disease, but two-thirds show no improvement. This has led to a search for a vaccine. For 15 years, the Houston Zoo and Dr. Paul Ling at Baylor College of Medicine’s Department of Virology and Microbiology have partnered to develop the drug. They have been helped by worldwide research from zoos and animal specialists, as well as graduate student Jessica Watts and Dr. Jeroen Pollet at Houston's Texas Children’s Hospital. The research has been funded by private donations, research partnerships, and grants.

Before being inoculated, the mRNA vaccine was exhaustively tested, with the dosage being extrapolated from data involving horses.

Houston Zoo veterinarians will periodically test Tess to see if she is developing the appropriate antibodies. If she is and there are no adverse reactions, the next step will be to administer the vaccine to the rest of the Houston herd. Many of these are Tess’s own children (Tucker, Tupelo, Tilly, and Teddy) and grandchildren (Winnie).

Should the vaccine prove effective, the doses will be made available worldwide to zoos and private elephant sanctuaries. It is likely to have a significant benefit on protecting and preserving the Asian Elephant population. As of January, there are fewer than 50,000 of the animas left in the wild. They are currently listed as endangered, and breeding programs and research done through the Houston Zoo are essential to keeping the animals from going extinct.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

8 can't-miss Houston business and innovation events for December

where to be

Editor's note: Houston’s innovation scene is loading up the calendar before the holidays. From climatetech pitch days to the return of favorite festive shindigs, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Dec. 3 — SouthWest-Midwest National Pediatric Device Innovation Consortium

This annual event brings together members, colleagues and guests of the FDA-supported pediatric consortium who are dedicated to assisting device innovators throughout the lifecycle in delivering innovative solutions to patients. Featured speakers include Dr. Danielle Gottlieb from Le Bonheur Children's Hospital, Balakrishna Haridas from Texas A&M University and Dr. Chester Koh from Texas Children’s Hospital.

This event is Wednesday, Dec. 3, from 3:30-8 p.m. at Texas A&M EnMed Tower. Register here.

Dec. 4 — Resiliency & Adaptation Sector Pitch Day: Scaling Solutions to Address Climate Disruption

Join innovators, industry leaders, investors and policymakers as they explore breakthrough climate and energy technologies at Greentown's latest installment of its Sector Pitch Day series, focused on resiliency and adaptation. Hear from Adrian Trömel, Chief Innovation Officer at Rice University; Eric Willman, Executive Director of the Rice WaTER Institute; pitches from 10 Greentown startups and more.

This event is Thursday, Dec. 4, from 1-3:30 p.m. at the Ion. The Ion Holiday Block Party follows. Register here.

Dec. 4 — The Ion District Holiday Block Party

The Ion District, Rice Alliance and Greentown Labs will celebrate the season during the Ion District Holiday Block Party. Expect to find local bites, drinks, music and meaningful connections across Houston’s innovation ecosystem. Guests are invited to participate in Operation Love’s holiday toy drive supporting local families.

This event is Thursday, Dec. 4, from 4-7 p.m. Register here.

Dec. 8 — Pumps & Pipes Annual Event 2025

The annual gathering brings together cross-industry leaders in aerospace, energy and medicine for engaging discussions and networking opportunities. Connor Grennan, Chief AI Architect at the NYU Stern School of Business, will present this year's keynote address, entitled "Practical Strategies to Increase Productivity." Other sessions will feature leaders from Cena Research Institute, NASA Ames Research Center, ExxonMobil, Southwest Airlines and more.

This event is Monday, Dec. 8, from 8 a.m.-5 p.m., at TMC Helix Park. Register here.

Dec. 9 — Jingle and Mingle

Don your ugliest sweater and snap a pic with Startup Santa! Bayou City Startups, Rocket Network, Founder Institute and Energytech Nexus are bringing back their popular Jingle Mingle for the third year. Network and celebrate with founders, community stakeholders and others in Houston's innovation scene. Donations to the Houston Food Bank are encouraged in place of tickets.

This event is Tuesday, Dec. 9, from 5-7 p.m., at the Solarium in Midtown. Register here.

Dec. 9 — European Innovation Spotlight

Celebrate European cooperation and innovation with the European Innovation Council during an exclusive demo night and networking event at Greentown Labs. Hear from 15 EIC-backed founders supported by the European Union with top-class climatetech technologies, listen to a fireside chat and engage in a networking event following the pitches.

This event is Tuesday, Dec. 9, from 4:30-7 p.m., at the Ion. Register here.

Dec. 9-10 — Energy LIVE

Energy LIVE is Reuters Events' flagship ConfEx that brings the full energy ecosystem together under one roof to solve the industry's most urgent commercial and operational challenges. The event will feature 3,000-plus senior executives across three strategic stages, a showcase of 75-plus exhibitors and six strategic content pillars.

This event is Dec. 9-10 at NRG Park. Register here.

Dec. 15 — Innov8 Hub Pitch Day

Hear pitches from members of the latest Innov8 Hub Innovators to Founders cohort, which empowers academic scientists and innovators to become successful startup founders. Meet and network with the founders over light bites and drinks at a reception following the pitch competition.

This event is Monday, Dec. 15, at the Innovation Center at UH Technology Bridge (Bldg. 4). Register here.

5 Houston suburbs among top places to retire and more innovation news

Trending Topics

Editor's note: It's time to look back on the top Houston innovation news in recent weeks. From Houston's most valuable startups right now to the top places to retire in 2026, here are the most-read InnovationMap stories from November 16-30:

1. U.S. News names 5 Houston suburbs as the best places to retire in 2026

The Woodlands is the No. 4 best place to retire. Photo courtesy of Visit The Woodlands

Houston-area suburbs should be on the lookout for an influx of retirees in 2026. A new study by U.S. News and World Report has declared The Woodlands and Spring as the fourth and fifth best cities to retire in America, with three other local cities making the top 25. Continue reading.

2. 3 Houston companies land on Deloitte’s Technology Fast 500 list

Three Houston companies ranked on Deloitte's annual list, with two cracking the top 100. Photo via Getty Images

Three Houston companies have made this year’s Deloitte North America Technology Fast 500 list. The report ranks the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. The top Houston company to make the list is Action1 Corp., No. 16, a provider of cybersecurity software. Continue reading.

3. Houston’s 10 most valuable startups revealed in new report

Houston's top startups by valuation range from e-commerce startups to a geothermal pioneer. Photo via Getty Images

The Greater Houston Partnership has released its list of the 10 most valuable startups that are fueling the city’s growth and entrepreneurial energy, including industry giants like Axiom Space and Fervo Energy. The list ranks its top 10 startups by valuation based on the company’s last private funding round, reflected in Pitchbook data, as of October 20 of this year. Continue reading.

4. Houston scores $120M in new cancer research and prevention grants

The Cancer Prevention and Research Institute of Texas has doled out 73 more grants to health care systems and companies in the state. Carter Smith/Courtesy of MD Anderson

The Cancer Prevention and Research Institute of Texas has granted more than $120 million to Houston organizations and companies as part of 73 new awards issued statewide. The funds are part of nearly $154 million approved by the CPRIT's governing board earlier this month, bringing the organization's total investment in cancer prevention and research to more than $4 billion since its inception. Continue reading.

5. Photos: Highlights from the 2025 Houston Innovation Awards

Congratulations to the 2025 Houston Innovation Awards winners! Photo by Emily Jaschke

The 2025 Houston Innovation Awards season came to a close on November 13 at InnovationMap's annual awards program and networking event. A full house of attendees gathered to celebrate the best and brightest in Houston innovation right now. Continue reading.

Houston scores $120M in new cancer research and prevention grants

cancer funding

The Cancer Prevention and Research Institute of Texas has granted more than $120 million to Houston organizations and companies as part of 73 new awards issued statewide.

The funds are part of nearly $154 million approved by the CPRIT's governing board earlier this month, bringing the organization's total investment in cancer prevention and research to more than $4 billion since its inception.

“Today marks an important milestone for CPRIT and for every Texan affected by cancer,” CEO Kristen Doyle said in a news release. “Texas has invested $4 billion in the fight against one of the world’s greatest public health challenges. Over 16 years, that support has helped Texas lead the search for breakthrough treatments, develop new cancer-fighting drugs and devices, and—most importantly—save tens of thousands of lives through early cancer detection and prevention. Every Texan should know this effort matters, and we’re not finished yet. Together, we will conquer cancer.”

A portion of the funding will go toward recruiting leading cancer researchers to Houston. CPRIT granted $5 million to bring John Quackenbush to Baylor College of Medicine. Quackenbush comes from the Harvard T.H. Chan School of Public Health and is an expert in computational and systems biology. His research focuses on complex genomic data to understand cancer and develop targeted therapies.

The University of Texas M.D. Anderson Cancer Center also received $3 million to recruit Irfan Asangani, an associate professor at the University of Pennsylvania Perelman School of Medicine. His research focuses on how chromatin structure and epigenetic regulation drive the development and progression of cancer, especially prostate cancer.

Other funds will go towards research on a rare, aggressive kidney cancer that impacts children and young adults; screening programs for breast and cervical cancer; and diagnostic technology.

In total, cancer grants were given to:

  • The University of Texas M.D. Anderson Cancer Center: $29.02 million
  • Baylor College of Medicine: $15.04 million
  • The University of Texas Health Science Center at Houston: $9.37 million
  • Texas A&M University System Health Science Center: $1.2 million
  • University of Houston: $900,000

Additional Houston-based companies landed grants, including:

  • Crossbridge Bio Inc.: $15.01 million
  • OncoMAGNETx Inc.: $13.97 million
  • Immunogenesis Inc.: $10.85 million
  • Diakonos Oncology Corporation: $7.16 million
  • Iterion Therapeutics Inc.: $7.13 million
  • NovaScan Inc.: $3.7 million
  • EMPIRI Inc.: $2.59 million
  • Air Surgical Inc.: $2.58 million
  • Light and Salt Association: $2.45 million

See the full list of awards here.

View All Listings